Evidence map›Paper›PMID 27234268›Full record

ArticleBrain : a journal of neurology2016

Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine.

Christoph J Schankin, Farooq H Maniyar, Youngho Seo, Shashidar Kori, Michael Eller, Denise E Chou, Joseph Blecha, Stephanie T Murphy, Randall A Hawkins, Till Sprenger and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain : a journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Imaging the inflammatory phenotype in migraine.The journal of headache and pain · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Role of Neuroinflammation and Blood-Brain Barrier Permutability on Migraine.International journal of molecular sciences · 2021
    Review
  17. Article
  18. Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  19. Article
  20. Lasmiditan mechanism of action - review of a selective 5-HTThe journal of headache and pain · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Christoph J Schankin1 Headache Group, Department of Neurology, University of California San Francisco, San Francisco, CA, USA 3 Department of Neurology, University Hospital Bern - Inselspital, University of Bern, Bern, Switzerland 4 Headache Group, NIHR-Wellcome Trust, King's Clinical Research Facility, King's College London, London, UK.
Farooq H Maniyar1 Headache Group, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Youngho Seo2 Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Shashidar Kori5 MAP Pharmaceuticals, Inc., Mountain View, CA, USA.
Michael Eller1 Headache Group, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Denise E Chou6 Department of Neurology, Columbia University Medical Center, New York, NY, USA.
Joseph Blecha2 Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Stephanie T Murphy2 Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Randall A Hawkins2 Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Till Sprenger7 Department of Neurology, DKD Helios Klinik, Wiesbaden, Germany.
Henry F VanBrocklin2 Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Peter J Goadsby1 Headache Group, Department of Neurology, University of California San Francisco, San Francisco, CA, USA 4 Headache Group, NIHR-Wellcome Trust, King's Clinical Research Facility, King's College London, London, UK peter.goadsby@kcl.ac.uk.
University of California, San Francisco · USUniversity of California System · USColumbia University Irving Medical Center · USEdison Pharmaceuticals (United States) · USHelios Kliniken · DEKing's College London · GBWellcome Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SEE DREIER DOI 101093/AWW112 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: For many decades a breakdown of the blood-brain barrier has been postulated to occur in migraine. Hypothetically this would facilitate access of medications, such as dihydroergotamine or triptans, to the brain despite physical properties otherwise restricting their entry. We studied the permeability of the blood-brain barrier in six migraineurs and six control subjects at rest and during acute glyceryl trinitrate-induced migraine attacks using positron emission tomography with the novel radioligand (11)C-dihydroergotamine, which is chemically identical to pharmacologically active dihydroergotamine. The influx rate constant Ki, average dynamic image and time activity curve were assessed using arterial blood sampling and served as measures for receptor binding and thus blood-brain barrier penetration. At rest, there was binding of (11)C-dihydroergotamine in the choroid plexus, pituitary gland, and venous sinuses as expected from the pharmacology of dihydroergotamine. However, there was no binding to the brain parenchyma, including the hippocampus, the area with the highest density of the highest-affinity dihydroergotamine receptors, and the raphe nuclei, a postulated brainstem site of action during migraine, suggesting that dihydroergotamine is not able to cross the blood-brain barrier. This binding pattern was identical in migraineurs during glyceryl trinitrate-induced migraine attacks as well as in matched control subjects. We conclude that (11)C-dihydroergotamine is unable to cross the blood-brain barrier interictally or ictally demonstrating that the blood-brain barrier remains tight for dihydroergotamine during acute glyceryl trinitrate-induced migraine attacks.

Indexed as

Blood-Brain BarrierMigraine DisordersAdultDihydroergotamineFemaleHumansMaleMiddle AgedNitroglycerinPositron-Emission TomographyVasoconstrictor AgentsVasodilator AgentsDihydroergotamineNitroglycerinVasoconstrictor AgentsVasodilator Agentsdrug treatmentheadacheimagingmigraine

Identifiers

PMID27234268
PMCPMC4939703
OpenAlexW2396552979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.